Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioFocus, a service division of Galapagos, and Astellas Pharma have entered into a collaboration agreement to discover novel targets in the field of central nervous system (CNS) disorders.
Subscribe to our email newsletter
As part of the agreement, BioFocus will use its SilenceSelect target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline.
BioFocus will receive research funding and success payments based on the progress of the collaboration.
BioFocus Galapagos Services SVP and MD Chris Newton said their target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology."
BioFocus’ discovery platform includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by chemogenomic and informatics tools, and compound library acquisition, storage and distribution services.